Drugmaker AbbVie has clinched a deal worth about $55 billion to acquire British rival Shire in the biggest tax inversion deal by a U.S. company. AbbVie and Shire said the new company will be incorporated in the UK, which will effectively drop AbbVie's tax rate by 2016 to 13% from 22.6% last year. In addition, AbbVie will expand its product portfolio, gaining access to Shire's rare-disease drugs. Shire shareholders will receive about 53 pounds a share in cash and stock. After AbbVie had four previous offers rejected, the announcement of the deal comes on the last day the companies had to reach an agreement, according to British takeover rules. TheStreet's Brittany Umar reports from New York.

More from Video

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home

KPMG Chair & CEO: There's No One-Size-Fits-All Approach to Diversity

KPMG Chair & CEO: There's No One-Size-Fits-All Approach to Diversity

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Best Buy's Billionaire Founder: We Were 'Late to the Game' in Online Shopping

Jim Cramer: Intuit Had a Fantastic Quarter

Jim Cramer: Intuit Had a Fantastic Quarter